Synonyms: GENZ-112638
eliglustat is an approved drug (FDA (2014), EMA (2015))
Compound class:
Synthetic organic
Comment: The marketed formulation contains eliglustat tartrate (PubChem CID 52918379).
|
|
No information available. |
Summary of Clinical Use ![]() |
Eliglustat is approved as a treatment for Gaucher disease type I [2-3]. This drug provides a twice daily, oral alternative to hormone replacement therapy. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Sufferers of Gaucher disease are defective in the production of the enzyme β-glucosidase (GBA, P04062), and this leads to the accumulation of its substrate, glucosylceramide. Excessive intracellular levels of this lipid may cause spleen and liver enlargement, anemia, excessive bleeding and bruising and bone disease. Eliglustat is a novel ceramide analogue designed to partially inhibit glucosylceramide synthase, an enzyme which is involved in the production of glucosylceramide. |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |